 SOMERVILLE, Mass., Aug. 10, 2021 GLOBE NEWSWIRE -- Finch Therapeutics Group, Inc. Finch or Finch Therapeutics Nasdaq: FNCH, a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced that Takeda Pharmaceutical Company Limited Takeda has elected to accelerate the transition of development responsibility for the FIN-524 ulcerative colitis development program. Takeda will assume primary development responsibility for the program, now known as TAK-524, ahead of the planned initiation of clinical-stage development. The transition will enable Takeda to leverage its expertise in inflammatory bowel disease IBD throughout the clinical development of FIN-524TAK-524. 